Having lived with disabling chronic pain for 32 years, one reader discovered a lesser known treatment that has transformed ...
Predicting who will transition from acute to chronic pain is the “holy grail” of pain neuroscience. A novel biomarker ...
Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Researchers found that mindfulness meditation can modify how a person experiences pain in a way that uses no drugs, proving ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...